MYGN

Business Context and Reporting Period

Company: Myriad Genetics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2002
Business Overview: Myriad is a fully integrated biopharmaceutical company operating two primary segments: Research (gene discovery, sequencing, and therapeutic product development) and Predictive Medicine (testing for disease predisposition). The company relies on strategic alliances with major pharmaceutical firms and has not yet attained profitability.

Key Financial Metrics

Segment Performance (Nine Months Ended Mar 31, 2002):

• Research Revenue: $20.58 million (Decreased 8% vs. prior year).
• Predictive Medicine Revenue: $19.14 million (Increased 60% vs. prior year).

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 16% year-over-year for the nine-month period, driven primarily by a 60% surge in Predictive Medicine revenue due to expanded sales efforts and wider medical acceptance. Conversely, Research revenue declined 8% due to the completion of prior collaborations (Bayer, TMRI) and a strategic shift toward internal drug development.
• Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 44% year-over-year ($17.6 million vs. $12.3 million), largely attributable to doubling the sales force from 53 to 106 full-time employees. Research and Development (R&D) expenses decreased slightly (4%) due to reimbursements from the affiliate Myriad Proteomics, Inc., offset by costs for the Flurizan clinical trial.
• Liquidity Position: Cash, cash equivalents, and marketable securities decreased by $15.1 million (11%) compared to the prior year, reflecting increased expenditures for internal drug development. Interest income dropped 19% due to lower cash balances and declining interest rates.
• Operating Loss: The operating loss widened to $11.19 million for the nine months ended March 31, 2002, compared to $9.68 million in the prior year period.

Outlook, Risks, and Management Commentary

• New Collaborations: In March 2002, the company announced two significant agreements: a drug discovery collaboration with Abbott Laboratories (up to $34 million potential value) for depression targets, and a $24 million research collaboration with DuPont/Pioneer Hi-Bred for agricultural genetics.
• Future Losses: Management expects to incur losses for at least the next several years due to the expansion of R&D, clinical trials, and the launch of new predictive medicine products.
• Liquidity Outlook: The company believes existing capital resources are sufficient to fund operations for at least the next two years. A shelf registration statement for up to $250 million in securities was filed in November 2002 (effective Nov 21, 2002) to raise funds when market conditions are favorable.
• Risks: Key risks include the inability to achieve commercial success for new products, delays in clinical trials, dependence on pharmaceutical collaborations, and the potential for patent infringement claims. The company also notes that operating results for interim periods may not be indicative of full-year results.

Investor Verification Checklist

• Revenue Sustainability: Verify if the 60% growth in Predictive Medicine revenue can be sustained given the significant increase in SG&A expenses (sales force expansion).
• Cash Burn Rate: Assess the trajectory of the $20.6 million operating cash outflow over nine months against the $58.6 million cash balance to confirm the "two-year runway" assertion.
• Collaboration Milestones: Monitor the progress and payment schedules of the new Abbott and DuPont collaborations to ensure they materialize as projected revenue sources.
• Deferred Revenue: Note the $9.3 million decrease in deferred revenue, indicating a shift from receiving upfront payments to recognizing revenue, which may impact future cash flow timing.
• Investment Portfolio: Review the composition of marketable securities ($67 million total) and the impact of unrealized losses on comprehensive income.